BiomX nabs $32 mln Series B
BiomX Ltd, an Israeli microbiome drug discovery company, has raised $32 million in Series B financing. The investors included OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., 8VC, MiraeAsset and Seventure Partners.
20 February 2019•1 min read
